Psilocybin vs Antidepressants: What the Head-to-Head Trial Found

In April 2021, Imperial College London published the first randomized controlled trial directly comparing psilocybin to an SSRI antidepressant. The results were published in *The New England Journal of Medicine* — one of the most prestigious medical journals in the world. Here's what they found. ## The Trial Design **Published in:** *The New England Journal of Medicine* **Lead researcher:** Robin Carhart-Harris **Enrolled:** 59 adults with moderate-to-severe major depressive disorder **Design:** Double-blind, randomized controlled trial Participants were randomly assigned to: - **Psilocybin group:** Two psilocybin sessions (25mg each) + 6 weeks of placebo capsules - **SSRI group:** Two placebo sessions + 6 weeks of escitalopram (10–20mg/day) Both groups received the same amount of psychological support. ## The Primary Outcome The primary outcome was change in depression severity (QIDS-SR-16 score) at 6 weeks. **Result:** Both groups showed significant reductions in depression severity. The psilocybin group showed slightly larger reductions, but the difference was not statistically significant. At first glance, this looks like a tie. But the secondary outcomes tell a more interesting story. ## The Secondary Outcomes The secondary outcomes showed consistent advantages for psilocybin: **Remission rates:** 57% of psilocybin participants achieved remission (QIDS-SR-16 score ≤5) vs 28% of SSRI participants. **Response rates:** 70% of psilocybin participants showed a significant response vs 48% of SSRI participants. **Emotional processing:** Psilocybin participants showed significantly greater improvements in "emotional blunting" — the emotional flatness that is a common complaint with SSRIs. The psilocybin group reported feeling more emotionally connected and alive. **Psychological flexibility:** Psilocybin participants showed significantly greater improvements in psychological flexibility — the ability to adapt thoughts and behaviors to changing circumstances. **Wellbeing and meaning:** Psilocybin participants reported significantly greater improvements in overall wellbeing, sense of meaning, and connectedness. ## What This Means The trial was not powered to detect a statistically significant difference between groups on the primary outcome — it was designed as a feasibility study. But the pattern of secondary outcomes is striking: psilocybin produced similar or superior antidepressant effects with additional benefits in emotional processing, psychological flexibility, and wellbeing that SSRIs don't produce. The SSRI group showed the typical SSRI pattern: reduced depression symptoms but also reduced emotional range. The psilocybin group showed reduced depression symptoms with enhanced emotional range. *This article is for informational purposes only and does not constitute medical advice.*